This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/wikipedia/
n17http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/pubchem-compound/
n21http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/drugbank/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/chemspider/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00923/identifier/chebi/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00923
rdf:type
n3:Drug
n3:description
Ceforanide is a second-generation parenteral cephalosporin antibiotic. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.
n3:generalReferences
# Crowle AJ, Sbarbaro JA, May MH: Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. Tubercle. 1988 Mar;69(1):15-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3140456 # Campoli-Richards DM, Lackner TE, Monk JP: Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1987 Oct;34(4):411-37. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3315624 # Cone LA, Barton SM, Woodard DR: Treatment of scleroma with ceforanide. Arch Otolaryngol Head Neck Surg. 1987 Apr;113(4):374-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3814386 # Barriere SL, Mills J: Ceforanide: antibacterial activity, pharmacology, and clinical efficacy. Pharmacotherapy. 1982 Nov-Dec;2(6):322-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6762529
n3:group
approved
n3:halfLife
2.6 to 2.98 hours
n3:indication
For the treatment of infections caused by susceptible organisms.
n3:manufacturer
n18:271B614A-363D-11E5-9242-09173F13E4C5 n18:271B614B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00923 n21:DB00923
dcterms:title
Ceforanide
adms:identifier
n6:39656 n7:DB00923 n8:3495 n9:43507 n10:C06884 n11:D00259 n12:46504532 n22:Ceforanide n23:PA164746057
n3:mechanismOfAction
The bactericidal activity of ceforanide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
n3:synonym
(6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Ceforanidum Ceforanide 7beta-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid 7-[O-(Aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid Ceforanido
n3:toxicity
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
n3:proteinBinding
80.6%
n16:hasConcept
n17:M0059859
n3:IUPAC-Name
n4:271B6150-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6156-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6155-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6152-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6153-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6154-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B614E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6166-363D-11E5-9242-09173F13E4C5 n4:271B614F-363D-11E5-9242-09173F13E4C5 n4:271B614C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B614D-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:J01DC11
n3:H-Bond-Acceptor-Count
n4:271B615C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B615D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6157-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6158-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B615A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6159-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B615B-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following intramuscular injection.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
60925-61-3
n3:category
n3:Bioavailability
n4:271B6162-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6164-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6165-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6161-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6160-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6163-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6151-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B615E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B615F-363D-11E5-9242-09173F13E4C5